Tag - KDNY

Feature

Chinook on a mission to change the course of kidney care

Chinook Therapeutics (NASDAQ:KDNY), which is developing three drug candidates to change the course of kidney care as well as a precision medicine pipeline of R&D programs, received a shot in the arm this month when...

June 27, 2023

Developments

Chinook, Ionis partner to develop antisense therapy for CKD

Chinook Therapies (NASDAQ:KDNY) entered into a collaboration agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe...

May 16, 2023

Markets

WB starts Chinook Therapeutics at OP

William Blair initiated coverage of Chinook Therapeutics (NASDAQ:KDNY) with an “outperform” rating. The stock closed at $14.60 on Oct. 5. Chinook recently completed a merger with Aduro Biotech to become a leading...

October 6, 2020

Tag - KDNY

Chinook on a mission to change the course of kidney care

Chinook, Ionis partner to develop antisense therapy for CKD

WB starts Chinook Therapeutics at OP

General

More